PMID- 37415136
OWN - NLM
STAT- MEDLINE
DCOM- 20230710
LR  - 20230718
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jul 6
TI  - Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced 
      hepatocellular carcinoma in the real world: a single-arm meta-analysis.
PG  - 635
LID - 10.1186/s12885-023-11112-w [doi]
LID - 635
AB  - BACKGROUND: Atezolizumab plus bevacizumab was approved in 2020 as a first-line 
      treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study 
      was to assess the curative effect and tolerability of the combination treatment 
      in advanced HCC. METHODS: Web of Science, PubMed and Embase were retrieved for 
      qualified literatures on the treatment of advanced HCC with atezolizumab plus 
      bevacizumab until September 1, 2022. The outcomes included pooled overall 
      response (OR), complete response (CR), partial response (PR), median overall 
      survival (mOS), median progression-free survival (mPFS), and adverse events 
      (AEs). RESULTS: Twenty-three studies, comprising 3168 patients, were enrolled. 
      The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy 
      response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 
      2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six 
      weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, 
      respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, 
      respectively. During the treatment, 83% and 30% of patients experienced any grade 
      AEs and grade 3 and above AEs, respectively. CONCLUSIONS: Atezolizumab in 
      combination with bevacizumab showed good efficacy and tolerability in the 
      treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose 
      therapy, atezolizumab plus bevacizumab in long-term, first-line, and 
      standard-dose treatment for advanced HCC showed a better tumor response rate.
CI  - (c) 2023. The Author(s).
FAU - Gao, Xiaoqiang
AU  - Gao X
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical 
      University, 28 Guiyi Street, Yunyan District, Guizhou, 550000, Guiyang, China.
FAU - Zhao, Rui
AU  - Zhao R
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical 
      University, 28 Guiyi Street, Yunyan District, Guizhou, 550000, Guiyang, China.
FAU - Ma, Huaxing
AU  - Ma H
AD  - Department of Emergency Surgery, Affiliated Hospital of Guizhou Medical 
      University, Guiyang, Guizhou, China.
FAU - Zuo, Shi
AU  - Zuo S
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical 
      University, 28 Guiyi Street, Yunyan District, Guizhou, 550000, Guiyang, China. 
      drzuoshi@gmc.edu.cn.
LA  - eng
GR  - [2022] 433/Science and Technology Support Project of Guizhou Province/
GR  - 82260535/National Natural Science Foundation of China/
GR  - gyfynsfc-2022-07/National Natural Science Foundation (Cultivation Project of 
      General Program) of Guizhou Medical University/
GR  - gyfynsfc-2021-34/National Natural Science Foundation of China (NSFC) Cultivation 
      Program of Affiliated Hospital of Guizhou Medical University/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230706
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Humans
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Bevacizumab/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Liver Neoplasms/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10327339
OTO - NOTNLM
OT  - Atezolizumab
OT  - Bevacizumab
OT  - Hepatocellular carcinoma
OT  - Meta-analysis
OT  - Single-arm
COIS- All the author declare that they have no confict of interest.
EDAT- 2023/07/07 01:05
MHDA- 2023/07/10 06:42
PMCR- 2023/07/06
CRDT- 2023/07/06 23:38
PHST- 2023/01/05 00:00 [received]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/07/10 06:42 [medline]
PHST- 2023/07/07 01:05 [pubmed]
PHST- 2023/07/06 23:38 [entrez]
PHST- 2023/07/06 00:00 [pmc-release]
AID - 10.1186/s12885-023-11112-w [pii]
AID - 11112 [pii]
AID - 10.1186/s12885-023-11112-w [doi]
PST - epublish
SO  - BMC Cancer. 2023 Jul 6;23(1):635. doi: 10.1186/s12885-023-11112-w.